Money and Medicine

Fortune Magazine: Adult Stem Cell Therapies Are Where Investors Should Be Looking

It is encouraging that the financial sector recognizes the tremendous advancements in adult stem cell research. When the rubber hits the road, the facts win out when making lucrative business decisions, as succinctly described in Fortune magazine this week. After five years of nothing but lies** in American print media (2004-2008) the truth is seeping through the cracks.

Fortune magazine reported this Tuesday, June 16, that researchers and analysts say that marketable therapies are already emerging from less controversial work with adult stem cells. According to this news piece “When it comes to stem cells, the public – and the media – tend to focus on embryos.” Regardless, as acknowledged by Fortune, “adult stem cells are currently the only type of stem cells used in transplants to treat diseases” and the successes attributed to the ease of use and reduced costs in developing therapies while avoiding ethical issues. From a business interest, many therapies are approaching market approval while embryonic stem cell therapies, if proven safe and successful, are at least 10 years away. While the media continues its focus on embryonic cells, industry recognizes where the value lies. Many major biopharmaceutical companies such as Pfizer and Genzyme are earmarking billions of dollars for development of adult stem cell cures. To read the entire article, please click here.

Patients have the right to know all available treatment options. For those reading this message for the first time, there are several resources available for research and clinical information. For additional information on successful adult stem cell studies, please click here. To find treatment centers for specific conditions, please visit the Repair Stem Cell Institute website.

**The first known breach of American print propaganda happened last November when the NY Times erred by allowing a truthful stem cell article on its website for the first time in many years. It seems their Paris correspondent, not knowing the “rules,” wrote an accurate description of a great adult stem cell victory. Before the bosses realized it, hundreds had read it. It was, of course, unceremoniously yanked and replaced by standard NY Times stem cell misinformation. (They actually had the chutzpah to call the adult stem cells “embryonic-like!”)